Figure 1.
NLRP3 expression in PBMCs (relative to rRNA beta-actin) (A), and IL-1β (B) and IL-18 (C) plasma concentrations in controls and training subjects (moderate-intensity and high-intensity groups) at baseline (pre-test) after 48 h (post-acute) and 12 weeks (post-chronic) from the start of the protocol. Data are presented as mean ± SD. * significant difference within groups with baseline (p ≤ 0.05). # significant difference between groups with the control group (p ≤ 0.05). ¤ significant difference between moderate and high intensity groups (p ≤ 0.05).